Literature DB >> 24189440

Role of melatonin, serotonin 2B, and serotonin 2C receptors in modulating the firing activity of rat dopamine neurons.

Franck Chenu1, Stacey Shim, Mostafa El Mansari, Pierre Blier.   

Abstract

Melatonin has been widely used for the management of insomnia, but is devoid of antidepressant effect in the clinic. In contrast, agomelatine which is a potent melatonin receptor agonist is an effective antidepressant. It is, however, a potent serotonin 2B (5-HT(2B)) and serotonin 2C (5-HT(2C)) receptor antagonist as well. The present study was aimed at investigating the in vivo effects of repeated administration of melatonin (40 mg/kg/day), the 5-HT(2C) receptor antagonist SB 242084 (0.5 mg/kg/day), the selective 5-HT(2B) receptor antagonist LY 266097 (0.6 mg/kg/day) and their combination on ventral tegmental area (VTA) dopamine (DA), locus coeruleus (LC) norepinephrine (NE), and dorsal raphe nucleus (DRN) serotonin (5-HT) firing activity. Administration of melatonin twice daily increased the number of spontaneously active DA neurons but left the firing of NE neurons unaltered. Long-term administration of melatonin and SB 242084, by themselves, had no effect on the firing rate and burst parameters of 5-HT and DA neurons. Their combination, however, enhanced only the number of spontaneously active DA neurons, while leaving the firing of 5-HT neurons unchanged. The addition of LY 266097, which by itself is devoid of effect, to the previous regimen increased for DA neurons the number of bursts per minute and the percentage of spikes occurring in bursts. In conclusion, the combination of melatonin receptor activation as well as 5-HT(2C) receptor blockade resulted in a disinhibition of DA neurons. When 5-HT(2B) receptors were also blocked, the firing and the bursting activity of DA neurons were both enhanced, thus reproducing the effect of agomelatine.

Entities:  

Keywords:  Ventral tegmental area; antidepressant; electrophysiology; melatonin; serotonin 2B receptor; serotonin 2C receptor

Mesh:

Substances:

Year:  2013        PMID: 24189440     DOI: 10.1177/0269881113510071

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  6 in total

1.  Complex patterns of dopamine-related gene expression in the ventral tegmental area of male zebra finches relate to dyadic interactions with long-term female partners.

Authors:  Sarah J Alger; Cynthia A Kelm-Nelson; Sharon A Stevenson; Charity Juang; Stephen C Gammie; Lauren V Riters
Journal:  Genes Brain Behav       Date:  2019-11-04       Impact factor: 3.449

2.  Activation of Melatonin Receptors Reduces Relapse-Like Alcohol Consumption.

Authors:  Valentina Vengeliene; Hamid R Noori; Rainer Spanagel
Journal:  Neuropsychopharmacology       Date:  2015-05-21       Impact factor: 7.853

3.  Serotonin-2B receptor antagonism increases the activity of dopamine and glutamate neurons in the presence of selective serotonin reuptake inhibition.

Authors:  Rami Hamati; Mostafa El Mansari; Pierre Blier
Journal:  Neuropsychopharmacology       Date:  2020-05-30       Impact factor: 7.853

4.  Attenuation of morphine physical dependence and blood levels of cortisol by central and systemic administration of ramelteon in rat.

Authors:  Majid Motaghinejad; Ozra Motaghinejad; Pantea Hosseini
Journal:  Iran J Med Sci       Date:  2015-05

5.  Melancholic-Like behaviors and circadian neurobiological abnormalities in melatonin MT1 receptor knockout mice.

Authors:  Stefano Comai; Rafael Ochoa-Sanchez; Sergio Dominguez-Lopez; Francis Rodriguez Bambico; Gabriella Gobbi
Journal:  Int J Neuropsychopharmacol       Date:  2015-01-31       Impact factor: 5.176

6.  Electroretinographic modifications induced by agomelatine: a novel avenue to the understanding of the claimed antidepressant effect of the drug?

Authors:  Michele Fornaro; Fabio Bandini; Luca Cestari; Christian Cordano; Carla Ogliastro; Claudio Albano; Domenico De Berardis; Matteo Martino; Andrea Escelsior; Giulio Rocchi; Pantaleo Fornaro; Concetta De Pasquale
Journal:  Neuropsychiatr Dis Treat       Date:  2014-05-20       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.